Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Healthcare Industry News How NanoPhoria’s record €83.5m raise could transform heart failure treatment—and put Italian biotech on the global map NanoPhoria Bioscience raises €83.5M to advance its novel heart-failure therapy and expand its nano delivery platform. Find out how it’s changing biotech today. byPallavi MadhirajuOctober 6, 2025